The compound you're asking about, **1,6-dimethyl-3-propylpyrimido[5,4-e][1,2,4]triazine-5,7-dione**, is a derivative of a fused ring system containing a pyrimidine and a triazine ring. While the specific compound itself may not be particularly well-known or widely studied, the **general structure** it represents, with its fused pyrimido[5,4-e][1,2,4]triazine core, is important in research due to its potential applications in several areas:
**1. Medicinal Chemistry:**
* **Anti-cancer activity:** Compounds with this core structure have been shown to exhibit promising anti-cancer activity. This is because they can interact with various biological targets involved in tumor growth and proliferation.
* **Antiviral activity:** Some derivatives have shown potential as antiviral agents, particularly against viruses like HIV.
* **Anti-inflammatory properties:** These compounds might exhibit anti-inflammatory activity by interfering with inflammatory pathways.
**2. Materials Science:**
* **Organic electronics:** The fused ring system can be incorporated into organic semiconductors, which are used in various electronic devices like organic light-emitting diodes (OLEDs) and solar cells.
* **Dye sensitization:** Derivatives of this structure can act as sensitizers in dye-sensitized solar cells, where they absorb light and transfer energy to generate electricity.
**3. Chemical Biology:**
* **Probes for biological processes:** This core structure can be modified to create fluorescent probes or other tools that can be used to study biological processes in cells and organisms.
**It is important to note that:**
* The specific activity and properties of the compound 1,6-dimethyl-3-propylpyrimido[5,4-e][1,2,4]triazine-5,7-dione are not readily available in scientific literature.
* The importance of this specific compound would depend on its specific biological or chemical activity, which needs to be investigated through further research.
* It's crucial to understand that the importance of a compound is often determined by its specific functional groups, modifications, and how these influence its interactions with biological systems or its properties in materials applications.
In conclusion, while the exact compound 1,6-dimethyl-3-propylpyrimido[5,4-e][1,2,4]triazine-5,7-dione may not be widely studied, the general structure it represents is of interest in research due to its potential applications in medicine, materials science, and chemical biology. Further investigation of specific derivatives could uncover valuable properties and applications for this class of compounds.
ID Source | ID |
---|---|
PubMed CID | 3164059 |
CHEMBL ID | 1325945 |
CHEBI ID | 92510 |
SCHEMBL ID | 15032586 |
Synonym |
---|
MLS000718932 , |
smr000291200 |
NCGC00093523-01 |
AKOS001873216 |
mfcd07188888 |
1,6-dimethyl-3-propylpyrimido[5,4-e][1,2,4]triazine-5,7-dione |
HMS2710G14 |
CHEMBL1325945 |
CCG-144064 |
us9073941, 617 |
bdbm34905 |
cid_3164059 |
1,6-dimethyl-3-propyl-pyrimido[5,4-e][1,2,4]triazine-5,7-quinone |
1,6-dimethyl-3-propyl-pyrimido[5,4-e][1,2,4]triazine-5,7-dione |
SCHEMBL15032586 |
sr-01000100610 |
SR-01000100610-1 |
CHEBI:92510 |
Q27164241 |
ml060 |
Class | Description |
---|---|
pyrimidotriazine | Any organic heterobicyclic compound containing ortho-fused pyrimidine and triazine rings. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 3.9811 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 5.0000 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 1.2589 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 39.8107 | 0.1259 | 19.1169 | 125.8920 | AID2549 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 3.5481 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 0.1000 | 20.8793 | 79.4328 | AID588456 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 4.6090 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
USP1 protein, partial | Homo sapiens (human) | Potency | 0.1000 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
TDP1 protein | Homo sapiens (human) | Potency | 1.3971 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 19.6221 | 0.1800 | 13.5574 | 39.8107 | AID1460; AID1468 |
thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 28.1838 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
Smad3 | Homo sapiens (human) | Potency | 1.1220 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
67.9K protein | Vaccinia virus | Potency | 0.7506 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
IDH1 | Homo sapiens (human) | Potency | 3.6626 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 2.8184 | 0.5406 | 17.6392 | 96.1227 | AID2528 |
galactokinase | Homo sapiens (human) | Potency | 1.3607 | 0.9431 | 15.2894 | 53.0367 | AID1868; AID2015 |
NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 3.1623 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 0.7892 | 0.0100 | 39.5371 | 1,122.0200 | AID1469; AID1567; AID1568; AID1570; AID1573 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 23.1093 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 5.0119 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
huntingtin isoform 2 | Homo sapiens (human) | Potency | 6.3096 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
DNA polymerase beta | Homo sapiens (human) | Potency | 50.1187 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 3.9811 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 2.3934 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 1.7884 | 0.1000 | 28.9256 | 213.3130 | AID588591; AID720502 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 1.5003 | 0.0501 | 27.0736 | 89.1251 | AID720496 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 2.1154 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 5.6234 | 0.0752 | 15.2253 | 39.8107 | AID485360 |
geminin | Homo sapiens (human) | Potency | 5.4869 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 35.4813 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 7.9433 | 0.0158 | 12.3113 | 615.5000 | AID1461 |
Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 14.1254 | 6.3096 | 60.2008 | 112.2020 | AID720709 |
Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 1.7783 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
Adenosine receptor A1 | Rattus norvegicus (Norway rat) | Potency | 1.7783 | 0.0631 | 4.1371 | 15.8489 | AID1868 |
Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | Potency | 0.7943 | 0.7943 | 12.2693 | 31.6228 | AID1568 |
Alpha-synuclein | Homo sapiens (human) | Potency | 35.4813 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 7.0795 | 1.9953 | 25.5327 | 50.1187 | AID624288 |
Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 2.8184 | 3.9811 | 46.7448 | 112.2020 | AID720708 |
phosphoglycerate kinase | Trypanosoma brucei brucei TREU927 | Potency | 2.7189 | 0.0757 | 8.4742 | 29.0628 | AID602233; AID686980 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
MPI protein | Homo sapiens (human) | IC50 (µMol) | 13.1900 | 0.1900 | 13.8256 | 50.1000 | AID1220 |
Phospholipase C, gamma 1 | Homo sapiens (human) | IC50 (µMol) | 1.5120 | 1.2120 | 3.1662 | 6.3720 | AID743329 |
phospholipase A2 precursor | Homo sapiens (human) | IC50 (µMol) | 80.0000 | 1.0200 | 9.0025 | 15.2000 | AID588400 |
dual specificity protein phosphatase 3 | Homo sapiens (human) | IC50 (µMol) | 3.2650 | 0.4000 | 9.3610 | 90.0000 | AID1654; AID1878 |
nuclear receptor coactivator 3 isoform 1 | Mus musculus (house mouse) | IC50 (µMol) | 5.0000 | 5.0000 | 5.0000 | 5.0000 | AID1984 |
cysteine protease ATG4B isoform a | Homo sapiens (human) | IC50 (µMol) | 2.8400 | 1.2500 | 10.6632 | 19.1000 | AID504756 |
tyrosine-protein phosphatase non-receptor type 22 isoform 1 | Homo sapiens (human) | IC50 (µMol) | 1.6910 | 0.4800 | 2.6449 | 8.3270 | AID435024; AID435027 |
tyrosyl-DNA phosphodiesterase 2 | Homo sapiens (human) | IC50 (µMol) | 0.1611 | 0.1611 | 3.9643 | 8.0090 | AID743297 |
exodeoxyribonuclease V subunit RecB | Escherichia coli str. K-12 substr. MG1655 | IC50 (µMol) | 118.4770 | 0.1000 | 0.1000 | 0.1000 | AID652151 |
exodeoxyribonuclease V subunit RecC | Escherichia coli str. K-12 substr. MG1655 | IC50 (µMol) | 118.4770 | 0.1000 | 0.1000 | 0.1000 | AID652151 |
dual specificity protein phosphatase 6 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1.2300 | 0.8320 | 24.1190 | 48.2000 | AID425 |
tyrosine-protein phosphatase non-receptor type 7 isoform 2 | Homo sapiens (human) | IC50 (µMol) | 1.2400 | 0.1000 | 12.7265 | 63.0000 | AID435032 |
Tyrosyl-DNA phosphodiesterase 2 | Homo sapiens (human) | IC50 (µMol) | 1.5100 | 0.9700 | 2.2160 | 4.1000 | AID765277 |
Renin | Homo sapiens (human) | IC50 (µMol) | 0.9800 | 0.0000 | 0.7796 | 8.2000 | AID1654 |
DNA-(apurinic or apyrimidinic site) endonuclease | Homo sapiens (human) | IC50 (µMol) | 200.0000 | 0.0550 | 2.9677 | 10.0000 | AID765293 |
RNA-editing ligase 1, mitochondrial | Trypanosoma brucei brucei | IC50 (µMol) | 0.4942 | 0.4108 | 1.4717 | 3.5100 | AID1117295 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Rac1 protein | Homo sapiens (human) | EC50 (µMol) | 0.6230 | 0.0202 | 5.9860 | 29.5100 | AID1340 |
cell division cycle 42 (GTP binding protein, 25kDa), partial | Homo sapiens (human) | EC50 (µMol) | 1.5500 | 0.0563 | 3.0554 | 13.5100 | AID1333; AID1334 |
delta-type opioid receptor | Homo sapiens (human) | EC50 (µMol) | 92.4980 | 0.1320 | 3.5864 | 9.5690 | AID588407; AID588411 |
mu-type opioid receptor isoform MOR-1 | Homo sapiens (human) | EC50 (µMol) | 92.4980 | 0.1320 | 3.3004 | 9.5690 | AID588407; AID588435 |
Tyrosyl-DNA phosphodiesterase 2 | Homo sapiens (human) | EC50 (µMol) | 0.5100 | 0.5100 | 1.7233 | 3.5000 | AID765294 |
Heat shock protein HSP 90-beta | Homo sapiens (human) | EC50 (µMol) | 0.9170 | 0.0040 | 0.2385 | 1.7000 | AID1799426 |
Heat shock protein HSP 90-beta | Homo sapiens (human) | Kd | 0.3080 | 0.0003 | 1.3330 | 9.8000 | AID1799424; AID1799425 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
MSH | Drosophila melanogaster (fruit fly) | AC50 | 4.6000 | 0.2090 | 9.5788 | 48.6900 | AID743444 |
Caspase 6, apoptosis-related cysteine peptidase | Homo sapiens (human) | AC50 | 0.0636 | 0.0636 | 11.2358 | 44.9700 | AID720632 |
DNA repair and recombination protein RAD54-like isoform 1 | Homo sapiens (human) | AC50 | 1.1300 | 0.8140 | 19.3119 | 78.9500 | AID651657 |
dual specificity tyrosine-phosphorylation-regulated kinase 1A | Rattus norvegicus (Norway rat) | AC50 | 0.2490 | 0.0056 | 4.6932 | 26.6940 | AID588345 |
Caspase-9 | Homo sapiens (human) | AC50 | 0.2140 | 0.2140 | 0.6237 | 1.3400 | AID743293 |
Caspase-8 | Homo sapiens (human) | AC50 | 0.3100 | 0.3100 | 12.4515 | 47.9700 | AID743294 |
Protein disulfide-isomerase A6 | Homo sapiens (human) | AC50 | 0.5130 | 0.5130 | 1.0015 | 1.4900 | AID720566 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID765294 | Inhibition of TDP2 (unknown origin) using 4-nitrophenyl phenylphosphonate as substrate after 60 mins | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Toxoflavins and deazaflavins as the first reported selective small molecule inhibitors of tyrosyl-DNA phosphodiesterase II. |
AID765293 | Inhibition of APE-1 (unknown origin) using double-stranded AP-site containing DNA as substrate after 30 mins by fluorescence assay | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Toxoflavins and deazaflavins as the first reported selective small molecule inhibitors of tyrosyl-DNA phosphodiesterase II. |
AID1604470 | Binding affinity to His6-tagged TPR2A (unknown origin) assessed as reduction in fluorescein-labeled C-terminal Hsp90/TRP2A protein-protein interaction incubated for 2 hrs by fluorescence polarization assay | 2020 | Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5 | Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions. |
AID1604471 | Antiproliferative activity against human MDA-MB-231 cells | 2020 | Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5 | Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions. |
AID765281 | Induction of redox cycling potential assessed as H2O2 production at 25 uM in presence of DTT | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Toxoflavins and deazaflavins as the first reported selective small molecule inhibitors of tyrosyl-DNA phosphodiesterase II. |
AID765277 | Inhibition of TDP2 (unknown origin) using 5'-Y-TCCGTTGAAGCCTGCTTT-3' as substrate after 60 mins | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Toxoflavins and deazaflavins as the first reported selective small molecule inhibitors of tyrosyl-DNA phosphodiesterase II. |
AID765292 | Inhibition of TDP1 (unknown origin) using double-stranded AP-site containing DNA as substrate at 100 uM after 30 mins by fluorescence assay relative to control | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Toxoflavins and deazaflavins as the first reported selective small molecule inhibitors of tyrosyl-DNA phosphodiesterase II. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1799426 | Cell Proliferation Assay from Article 10.1021/cb800162x: \\A novel class of small molecule inhibitors of Hsp90.\\ | 2008 | ACS chemical biology, Oct-17, Volume: 3, Issue:10 | A novel class of small molecule inhibitors of Hsp90. |
AID1799424 | AlphaScreen Assay from Article 10.1021/cb800162x: \\A novel class of small molecule inhibitors of Hsp90.\\ | 2008 | ACS chemical biology, Oct-17, Volume: 3, Issue:10 | A novel class of small molecule inhibitors of Hsp90. |
AID1799425 | Fluorescence Polarization Assay from Article 10.1021/cb800162x: \\A novel class of small molecule inhibitors of Hsp90.\\ | 2008 | ACS chemical biology, Oct-17, Volume: 3, Issue:10 | A novel class of small molecule inhibitors of Hsp90. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (25.00) | 29.6817 |
2010's | 4 (50.00) | 24.3611 |
2020's | 2 (25.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.15) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (12.50%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (87.50%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |